Clinical Study of CWP232291 in Acute Myeloid Leukemia Patients
Status:
Unknown status
Trial end date:
2020-10-01
Target enrollment:
Participant gender:
Summary
This is a multicenter (S. Korea/US), Phase Ib, open-label, dose-finding study to assess
safety, PK, PD, and preliminary efficacy of CWP232291 administered in combination with ara-C
in subjects with relapsed or refractory AML.
The primary objectives in phase 2a is to assess the efficacy of CWP232291 administered in
combination with cytarabine (response rate complete remission [RR-CR]/complete remission with
incomplete blood count recovery [CRi]/partial remission [PR]).